GSK’s Arexvy Is First RSV Vaccine Approved By FDA, But A Second Is Poised To Follow

Arexvy will launch in the US in time for the fall 2023 RSV season for adults 60 and older, GSK said. Pfizer’s Abrysvo is also pending at the FDA.